Structure-function Based Molecular Relationships in Ewing's Sarcoma

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Feb 18

PMID 25688366

Citations 5

Authors

Roumiana Todorova

Affiliations

Soon will be listed here.

Abstract

Ewing's Sarcoma Oncogene (ews) on chromosome 22q12 is encoding a ubiquitously expressed RNA-binding protein (EWS) with unknown function that is target of tumor-specific chromosomal translocations in Ewing's sarcoma family of tumors. A model of transcription complex was proposed in which the heterodimer Rpb4/7 binds to EAD, connecting it to Core RNA Pol II. The DNA-binding domain, provided by EFP, is bound to the promoter. Rpb4/7 binds RNA, stabilizing the transcription complex. The complex Rpb4/7 can stabilize the preinitiation complexes by converting the conformation of RNA Pol II. EWS may change its conformation, so that NTD becomes accessible. Two different mechanisms of interaction between EWS and RNA Pol II are proposed: (I) an intermolecular EWS-EWS interaction between two molecules, pushing conformation from "closed" to "open" state, or (II) an intramolecular interaction inside the molecule of EWS, pushing conformation of the molecule from "closed" to "open" state. The modified forms of EWS may interact with Pol II subunits hsRpb5 and hsRpb7. The EWS and EFPs binding partners are described schematically in a model, an attempt to link the transcription with the splicing. The proposed model helps to understand the functional molecular interactions in cancer, to find new partners and ways to treat cancer.

Citing Articles

Fuzzy Drug Targets: Disordered Proteins in the Drug-Discovery Realm.

Saurabh S, Nadendla K, Purohit S, Sivakumar P, Cetinel S ACS Omega. 2023; 8(11):9729-9747.

PMID: 36969402 PMC: 10034788. DOI: 10.1021/acsomega.2c07708.

Intrinsically Disordered Proteins as Regulators of Transient Biological Processes and as Untapped Drug Targets.

Hosoya Y, Ohkanda J Molecules. 2021; 26(8).

PMID: 33917117 PMC: 8067799. DOI: 10.3390/molecules26082118.

RNA polymerase II subunit 3 regulates vesicular, overexpressed in cancer, prosurvival protein 1 expression to promote hepatocellular carcinoma.

Hu P, Wang B, Chen T, Xu Y, Zheng G, Zhu Y J Int Med Res. 2021; 49(4):300060521990512.

PMID: 33845647 PMC: 8047087. DOI: 10.1177/0300060521990512.

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Pishas K, Drenberg C, Taslim C, Theisen E, Johnson K, Saund R Mol Cancer Ther. 2018; 17(9):1902-1916.

PMID: 29997151 PMC: 6201274. DOI: 10.1158/1535-7163.MCT-18-0373.

EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity.

Siegfried A, Rousseau A, Maurage C, Pericart S, Nicaise Y, Escudie F Brain Pathol. 2018; 29(1):53-62.

PMID: 29679497 PMC: 8028282. DOI: 10.1111/bpa.12619.

References

Corbi N, Di Padova M, De Angelis R, Bruno T, Libri V, Iezzi S . The alpha-like RNA polymerase II core subunit 3 (RPB3) is involved in tissue-specific transcription and muscle differentiation via interaction with the myogenic factor myogenin. FASEB J. 2002; 16(12):1639-41. DOI: 10.1096/fj.02-0123fje. View

Yang L, Chansky H, Hickstein D . EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem. 2000; 275(48):37612-8. DOI: 10.1074/jbc.M005739200. View

Woychik N, Hampsey M . The RNA polymerase II machinery: structure illuminates function. Cell. 2002; 108(4):453-63. DOI: 10.1016/s0092-8674(02)00646-3. View

Kovar H . Downstream EWS/FLI1 - upstream Ewing's sarcoma. Genome Med. 2010; 2(1):8. PMC: 2829933. DOI: 10.1186/gm129. View

Choder M . Rpb4 and Rpb7: subunits of RNA polymerase II and beyond. Trends Biochem Sci. 2004; 29(12):674-81. DOI: 10.1016/j.tibs.2004.10.007. View

Knoop L, Baker S . The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem. 2000; 275(32):24865-71. DOI: 10.1074/jbc.M001661200. View

Belyanskaya L, Gehrig P, Gehring H . Exposure on cell surface and extensive arginine methylation of ewing sarcoma (EWS) protein. J Biol Chem. 2001; 276(22):18681-7. DOI: 10.1074/jbc.M011446200. View

Yang L, Hu H, Zielinska-Kwiatkowska A, Chansky H . FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells. Biochem Biophys Res Commun. 2010; 402(1):129-34. PMC: 2981438. DOI: 10.1016/j.bbrc.2010.09.129. View

Lyabin D, Doronin A, Eliseeva I, Guens G, Kulakovskiy I, Ovchinnikov L . Alternative forms of Y-box binding protein 1 and YB-1 mRNA. PLoS One. 2014; 9(8):e104513. PMC: 4130533. DOI: 10.1371/journal.pone.0104513. View

10.

Spahn L, Petermann R, Siligan C, Schmid J, Aryee D, Kovar H . Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. Cancer Res. 2002; 62(16):4583-7. View

11.

Uversky V, Oldfield C, Midic U, Xie H, Xue B, Vucetic S . Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics. 2009; 10 Suppl 1:S7. PMC: 2709268. DOI: 10.1186/1471-2164-10-S1-S7. View

12.

Zhang D, Paley A, Childs G . The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem. 1998; 273(29):18086-91. DOI: 10.1074/jbc.273.29.18086. View

13.

Linding R, Jensen L, Diella F, Bork P, Gibson T, Russell R . Protein disorder prediction: implications for structural proteomics. Structure. 2003; 11(11):1453-9. DOI: 10.1016/j.str.2003.10.002. View

14.

Anderson J, Denny C, Tap W, Federman N . Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr Res. 2012; 72(2):112-21. PMC: 4283808. DOI: 10.1038/pr.2012.54. View

15.

Nakajima T, Uchida C, Anderson S, Lee C, Hurwitz J, Parvin J . RNA helicase A mediates association of CBP with RNA polymerase II. Cell. 1997; 90(6):1107-12. DOI: 10.1016/s0092-8674(00)80376-1. View

16.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A . Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. Nucleic Acids Res. 2013; 41(19):8853-71. PMC: 3799442. DOI: 10.1093/nar/gkt678. View

17.

Erkizan H, Uversky V, Toretsky J . Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin Cancer Res. 2010; 16(16):4077-83. PMC: 3682924. DOI: 10.1158/1078-0432.CCR-09-2261. View

18.

Heyerdahl S, Rozenberg J, Jamtgaard L, Rishi V, Varticovski L, Akah K . The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. Eur J Cell Biol. 2010; 89(7):564-73. PMC: 7316388. DOI: 10.1016/j.ejcb.2009.11.029. View

19.

Plougastel B, ZUCMAN J, Peter M, Thomas G, Delattre O . Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics. 1993; 18(3):609-15. DOI: 10.1016/s0888-7543(05)80363-5. View

20.

Herrero-Martin D, Fourtouna A, Niedan S, Riedmann L, Schwentner R, Aryee D . Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma. 2011; 2011:352580. PMC: 3216314. DOI: 10.1155/2011/352580. View